Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CTSS | P25774 | 7/20 | 0.46 |
| ▸ | CTSK | P43235 | 6/20 | 0.46 |
| ▸ | PTPRB | P23467 | 1/20 | 0.37 |
| ▸ | GABRB1 | P18505 | 1/20 | 0.36 |
| ▸ | GABRB2 | P47870 | 1/20 | 0.36 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.36 |
| ▸ | ATM | Q13315 | 1/20 | 0.35 |
| ▸ | CCR2 | P41597 | 1/20 | 0.35 |
| ▸ | S1PR3 | Q99500 | 1/20 | 0.35 |
| ▸ | CA1 | P00915 | 1/20 | 0.35 |
| ▸ | CA2 | P00918 | 1/20 | 0.35 |
| ▸ | CA7 | P43166 | 1/20 | 0.35 |
| ▸ | CHRNB2 | P17787 | 1/20 | 0.34 |
| ▸ | CHRNB4 | P30926 | 1/20 | 0.34 |
| ▸ | CHRNA3 | P32297 | 1/20 | 0.34 |
| ▸ | CHRNA4 | P43681 | 1/20 | 0.34 |
| ▸ | TRPA1 | O75762 | 1/20 | 0.34 |
| ▸ | CTSL | P07711 | 1/20 | 0.34 |
| ▸ | CTSB | P07858 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1095706 | 1.00 | CTSS (0.46) | CTSSCTSKPTPRBGABRB1GABRB2 | |
| SCHEMBL1105000 | 0.87 | CTSS (0.49) | CTSSCTSKPTPRBALOX5ATM | |
| SCHEMBL3648561 | 0.87 | CTSS (0.49) | CTSSCTSKPTPRBALOX5ATM | |
| SCHEMBL1095127 | 0.87 | CTSS (0.49) | CTSSCTSKPTPRBALOX5ATM | |
| SCHEMBL20281196 | 0.86 | CTSS (0.46) | CTSSCTSKPTPRBALOX5ATM | |
| SCHEMBL8253342 | 0.86 | CTSS (0.46) | CTSSCTSKPTPRBGABRB1GABRB2 | |
| SCHEMBL5873431 | 0.81 | CTSK (0.63) | CTSSCTSKGABRB1GABRB2ATM | |
| SCHEMBL5873392 | 0.81 | CTSK (0.63) | CTSSCTSKGABRB1GABRB2ATM | |
| SCHEMBL5873395 | 0.81 | CTSK (0.63) | CTSSCTSKGABRB1GABRB2ATM | |
| SCHEMBL4789660 | 0.77 | CTSS (0.48) | CTSSCTSKPTPRBATMCA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2546239-B1 | 6-AMINO ISOQUINOLINS COMPOUNDS AND METHODS FOR MAKING THE SAME | AERIE PHARMACEUTICALS INC (US) | 2015-04-08 | — | — | EP | disclosed |
| US-8871757-B2 | 6-and 7-amino isoquinoline compounds and methods for making and using the same | AERIE PHARMACEUTICALS, INC. (US) | 2014-10-28 | — | — | US | disclosed |
| US-8871757-B2 | 6-and 7-amino isoquinoline compounds and methods for making and using the same | AERIE PHARMACEUTICALS, INC. (US) | 2014-10-28 | — | — | US | disclosed |
| US-8871757-B2 | 6-and 7-amino isoquinoline compounds and methods for making and using the same | AERIE PHARMACEUTICALS, INC. (US) | 2014-10-28 | — | — | US | disclosed |
| US-8455514-B2 | 6-and 7-amino isoquinoline compounds and methods for making and using the same | AERIE PHARMACEUTICALS, INC. (US) | 2013-06-04 | — | — | US | disclosed |
| US-8455514-B2 | 6-and 7-amino isoquinoline compounds and methods for making and using the same | AERIE PHARMACEUTICALS, INC. (US) | 2013-06-04 | — | — | US | disclosed |
| US-8455514-B2 | 6-and 7-amino isoquinoline compounds and methods for making and using the same | AERIE PHARMACEUTICALS, INC. (US) | 2013-06-04 | — | — | US | disclosed |
| EP-2546239-A1 | 6-AMINO ISOQUINOLINS COMPOUNDS AND METHODS FOR MAKING THE SAME | AERIE PHARMACEUTICALS, INC. (US) | 2013-01-16 | — | — | EP | disclosed |
| EP-2546237-A1 | 7-AMINO ISOQUINOLINS COMPOUNDS AND METHODS FOR MAKING THE SAME | AERIE PHARMACEUTICALS, INC. (US) | 2013-01-16 | — | — | EP | disclosed |
| EP-2252589-B1 | 6-AND 7-AMINO ISOQUINOLINE COMPOUNDS AND METHODS FOR MAKING AND USING THE SAME | AERIE PHARMACEUTICALS INC (US) | 2012-11-21 | — | — | EP | disclosed |
| US-8153654-B2 | — | — | 2012-04-10 | — | — | US | disclosed |
| US-8153654-B2 | — | — | 2012-04-10 | — | — | US | disclosed |
| EP-2252589-A2 | 6-AND 7-AMINO ISOQUINOLINE COMPOUNDS AND METHODS FOR MAKING AND USING THE SAME | Aerie Pharmaceuticals, Inc. (US) | 2010-11-24 | — | — | EP | disclosed |
| US-20100144713-A1 | 6-AND 7-AMINO ISOQUINOLINE COMPOUNDS AND METHODS FOR MAKING AND USING THE SAME | AERIE PHARMACEUTICALS, INC. (US) | 2010-06-10 | — | — | US | disclosed |
| US-20100144713-A1 | 6-AND 7-AMINO ISOQUINOLINE COMPOUNDS AND METHODS FOR MAKING AND USING THE SAME | AERIE PHARMACEUTICALS, INC. (US) | 2010-06-10 | — | — | US | disclosed |
| WO-2009091898-A2 | 6-AND 7-AMINO ISOQUINOLINE COMPOUNDS AND METHODS FOR MAKING AND USING THE SAME | AERIE PHARMACEUTICALS, INC. (US) | 2009-07-23 | — | — | WO | disclosed |
| US-20090186917-A1 | 6-And 7-amino isoquinoline compounds and methods for making and using the same | AERIE PHARMACEUTICALS, INC. (US) | 2009-07-23 | — | — | US | disclosed |
| US-20090186917-A1 | 6-And 7-amino isoquinoline compounds and methods for making and using the same | AERIE PHARMACEUTICALS, INC. (US) | 2009-07-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100144713-A1 | 6-AND 7-AMINO ISOQUINOLINE COMPOUNDS AND METHODS FOR MAKING AND USING THE SAME | COQ8A, MAP3K7, PRKG2 | CTSS 2629/4885CTSK 813/4885PTPRB 3824/4885 |
| US-20090186917-A1 | 6-And 7-amino isoquinoline compounds and methods for making and using the same | COQ8A, MAP3K7, PRKG2 | CTSS 2629/4885CTSK 813/4885PTPRB 3824/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.